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Abstract
Background: Current testing of symptomatic patients for
SARS-CoV-2 involves the use of nucleic acid amplification
tests, also known as genetic, RNA, or polymerase chain reaction (PCR), to detect viral RNA. The initial use of point of
care (POC) antibody tests, also known as serological tests, in
the management of SARS-CoV-2 infection was limited. In this
review, we determine the significance of POC antibody serological tests and explore their possible role in the diagnosis
and management of patients infected with the SARS-CoV-2
virus.
Methods: A literature search was conducted in Google
Scholar, PubMed, and Embase, supplemented by searching
the Centers for Disease Control and Prevention (CDC) and
Infectious Diseases Society of America (IDSA) websites. We
identified seven articles published in the last six months pertaining to our search. The sensitivity and specificity statistics
of IgG/IgM antibody tests obtained from these studies were

Introduction
IgG and IgM are among the different types of antibodies produced during an immunological response to
a pathogen. Detection of IgM in the body indicates
a recent infection while the presence of IgG indicates
a prior exposure to the same pathogen or a chronic
infection. The two major antigenic targets of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV2) virus against which antibodies are detected are spike
glycoprotein (S) and nucleocapsid phosphoprotein (N).
As per CDC, SARS-CoV-2 infection is unusual as there
is simultaneous appearance of both IgG and IgM antibodies in the serum within 2-3 weeks after the onset of
illness. Therefore, detection of IgM without IgG is uncommon during this timeframe.[1] Studies indicate that
serological tests can detect the presence of SARs-CoV-2
IgG and IgM antibodies as early as day 4 after symptom
onset, however, antibodies could be also be detected in
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compared and used to determine the clinical importance of
rapid diagnostic antibody tests for SARS-CoV-2.
Results: Through the literature review, it was found that POC
diagnostic antibody tests can be used as an adjuvant with
nucleic acid amplification tests in determining both active
and post-exposure antibodies. These rapid antibody IgG/IgM
tests had high sensitivity—the ability of a test to correctly
identify those with the disease—and high specificity—the ability of a test to correctly identify those without the disease.
Conclusion: Emerging studies indicate the importance of
POC antibody serological testing as a diagnostic tool in the
current SARS-CoV-2 pandemic. Considering the limitations
of the molecular methods of testing, POC antibody tests can
help reduce dependency on molecular assays when used in
conjunction with them.

the middle and later course of the disease.[2] Most patients seroconvert around 7-11 days post-exposure to
the virus.[3] One study found that the IgM antibodies
initially increased followed by a decline while the IgG
antibody levels stabilized over time. IgG antibody levels were also found to double after the PCR resulted
negative.[4] Another study found that the average levels of IgM and IgA antibodies increased within 6-8 days
from the onset of symptoms. Compared to the IgM antibody, IgA antibody showed persistently higher levels for the whole observation period, with a peak level
at 20-22 days.[5] The detection of the antibodies collectively at the time when the PCR becomes negative
implied that they may have a role in the clearance of
the virus.[2] While one study linked the appearance
of antibodies with the severity of the disease, another
study revealed that it may be independent of the clinical course of the disease.[6] It was also found that high
antibody levels may help in the progression of the in-
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fection as high viral load lead to strong extra-follicular
B cell stimulation leading to rapid antibody production which doesn’t follow the sequential change from
IgM to IgG. Such antibodies stimulate cytokine storm
which has been implicated in acute lung injury associated with COVID-19 infection.[6] Many patients were
found to be seropositive within the course of illness for
more than 30 days.[2] However, a negative serological
test does not exclude COVID-19 infection as many patients were found to be seronegative during the early
course of the infection.[4] Hence the results of these
serological assays may be inconclusive during the early
course of the disease.
The CDC categorizes antibody tests into two broad categories: 1) Binding antibody detection tests and 2) neutralizing antibody tests. While the use of neutralizing
antibody tests has not been approved by the US-FDA,
the binding antibody tests are widely employed in the
detection of the IgG and IgM antibodies. These tests detect the presence of different types of antibodies against
different components of the SARS-CoV-2 virus using
purified proteins of the virus. Specific reagents are used
to identify individual antibody types such as IgG, IgM,
and IgA. These tests are further classified into point
of care tests (POC) such as lateral flow immunochromatography assays (LFIA) and laboratory-based tests
such as Enzyme-linked immunosorbent assay (ELISA)
and chemiluminescent assay (CIA). POC tests are performed at the time and place of patient care such as the
patient’s bedside or the physician’s office. These tests
use lateral flow devices to detect IgG or IgG and IgM or
total antibody in serum, plasma, whole blood, saliva.
While the POC tests can be performed in a field setting, lab-based tests require trained laboratorians and
a specialized setting. IgG/IgM rapid tests are the two
available point of care, qualitative antibody detection
tests.[1]
The current recommendations of the CDC heavily depend upon the use of reverse transcriptase polymerase
chain reaction (RT-PCR) for the qualitative detection of
SARS-CoV-2 viral nucleic acid for the diagnosis and
the management of the COVID-19. In the wake of the
increasing emergence of challenges and limitations of
the molecular tests, the importance of rapid diagnostic antibody tests has increased, and their role is being
rapidly explored.[7] In our review, we explore the role
of the POC antibody tests.

Methods
For our article, literature contained in Google Scholar,
PubMed, and Embase, as well as websites for the
Center for Disease Control (CDC) and the Infectious
Diseases Society of America (IDSA) database, was
searched using combinations of keywords ‘SARS-CoV2’, ‘coronavirus’, ‘COVID-19 pandemic’, ‘health care

ULJRI | https://ir.library.louisville.edu/jri/vol4/iss1/70

Role of Point of Care Antibody Tests in Diagnosis of SARS-CoV-2

workers’, ‘molecular test’, ‘diagnostic tests’, ‘serological tests’ and their variants. The articles used for the
review were published within the last 6 months (December 2019 to June 2020).

Results
Seven studies were eligible for inclusion in this review.
All the included studies used immunochromatography method of POC IgG/IgM antibody test. The tests
were conducted on blood or plasma or serum samples. Spicuzza et al, Ying et al, Zhengtu et al, Dohla
et al, and Choe et al used combined IgG/IgM antibody kit and divided patients in two groups.[8-12]
One group had patients who tested positive for SARSCoV-2 using RT-PCR while the second group had patients who were suspected of having COVID-19 infection, but tested negative on an RT-PCR. Hoffman et
al conducted the study by dividing their patients in a
similar manner, but they used rapid IgG-IgM detection test which detected IgG and IgM antibody separately.[13] While Xiang et also used rapid IgG-IgM antibody detection kit detecting the antibodies separately,
they tested patients diagnosed with a positive viral RTPCR in both groups.[14] They tested one of the groups
with laboratory-based ELISA antibody test while the
other group was tested using the rapid IgG-IgM POC
antibody test. These studies calculated the sensitivities
and specificities of the test, which can be seen in Table
1.

Discussion
It was observed that the overall sensitivity and specificity of these antibody tests was high except for Dohla
et al. The antibody tests also yielded high sensitivity
and specificity for the detection of individual IgG/IgM
antibodies. The results indicate that these tests could
play a very important role in diagnosis of SARS-CoV-2
infection when used in conjunction with the molecular
tests. The rapid diagnostic POC test could be preferred
over the laboratory-based antibody test. Hence, the
rapid diagnostic IgG/IgM antibody tests can be used
in conjunction with the molecular test. These tests are
faster, less expensive, easy to use, accessible to staff
without lab training and are higher specificity versus
the laboratory-based antibody test.[2, 4, 15] These antibody tests have also been found to be beneficial in
diagnosing patients with a prolonged clinical course.
They can be used to diagnose patients with a prolonged
course of illness, who get a false negative result on
the PCR.[2] They can diagnose patients who have recovered from a prior asymptomatic infection. These
asymptomatic patients may have a positive IgG, a negative IgM, a negative molecular test with no prior history of COVID-19 infection.[16] POC antibody tests can
also be used for contact tracing, serological surveil-
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Specificity: 96.2%(95% CI: 89.3-99.2)

Sensitivity: 93%(95% CI: 84.1-97.6)

Sample size: 149

Specificity: 90%

Sensitivity: 36.4%

Sample size: 49

Specificity: 91% (12/128)

Sensitivity: 89% (352/397)

Sample size: 397

Specificity (IgG): 99% (123/124)

Specificity (IgM): 100% (124/124)

Sensitivity (IgG): 99% (27/29)

Sensitivity (IgM): 69% (20/29)

Sample size: 153

Specificity: 100% (35/35)

Sensitivity: 82(75/91)

Sample size: 154

Specificity: 91% (8/89)

Sensitivity: 85% (77/90)

Sample size: 179

Specificity: 92.8%

Sensitivity: 82.6%

Sample size: 37

Results

The immunochromatography-based COVID-19 IgG/IgM rapid test is a
useful and practical diagnostic assay for practical diagnostic assay for
detection of COVID-19, especially in the presence of IgM or IgG
antibodies.

Rapid antibody test have low sensitivity and is not recommended for
community screening.

The IgM-IgG combined assay has better utility and sensitivity compared
with a single IgM or IgG test. It can be used for the rapid screening of
SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals,
clinics, and test laboratories

The test is suitable for assessing previous virus exposure, although
negative results may be unreliable during the first few weeks after
infection.

Although ELISA and GICA are simple, fast, and safe, the results can be
used for clinical reference

The sensitivity and specificity of the IgG/IgM combined test kit is
adequate, with short turnaround time, no specific requirements for
additional equipment or skilled technicians, all of these collectively
contribute to its competence for mass testing. At the current stage,it
cannot replace SARA-CoV-2 nucleic acid RT-PCR, but it can serve as a
complementary option with RT-PCR.

In patients presenting with a discrepancy between the clinical/
radiological feature and the molecular test, the rapid antibody detection
might be an additional element helping the clinician to make a correct
diagnosis

Summary

Table 1. Studies considered for our review.
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lance at local, regional, state, and national levels. They
can identify possibly immune patients and individuals
who could be a source of therapeutic or prophylactic
neutralizing antibodies and vaccine trials.[15, 17] How-

ever, the use of these assays cannot be used to determine immune status in individuals until the presence,
durability and duration of immunity is established.[1]
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